Volume growth deceleration
Patient volume growth slowed to 2.7% in Q3 due to unexpected decline in seasonal fever portfolio, raising concerns about sustained volume recovery.
LALPATHLAB / Q3-FY26 / risks
Keep the risk register visible.
Dr. Lal Path Labs · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
Franchise-led margin dilution
Analyst raised concern that revenue sharing with franchise network (over 25% in Delhi) could dilute margins; management argued operating leverage offsets it.
Currency impact on reagent costs
INR depreciation may increase imported reagent costs; management has long-term contracts but may need to review pricing if dollar continues to rise.
Radiology ramp-up uncertainty
Advanced radiology pilot is still early; management noted it is unlikely to be a significant contributor to topline in the next 2-3 years.